Jaglena Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Adult dose

This medication is administered as a single daily dose of 100 mg, and the maximum daily dose is 100 mg. It can be taken regardless of meals. In patients with renal impairment, dosage adjustments are necessary based on the glomerular filtration rate (GFR). - In mild renal impairment (eGFR 60–90 mL/min/1.73 m²) and moderate renal impairment (eGFR 45–60 mL/min/1.73 m²): No dosage adjustment needed - Severe renal impairment patients (GFR < 30 mL/min/1.73 m²) or those requiring hemodialysis or peritoneal dialysis (ESRD) should receive 25 mg once daily.

This medication can cause rare but serious allergic reactions, so if symptoms such as rash or difficulty breathing occur, it should be discontinued immediately and a doctor should be consulted. This medication may cause pancreatitis, a condition involving inflammation of the pancreas, so if there is abdominal pain, vomiting, or severe abdominal discomfort, medical personnel should be notified immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, nor should individuals with allergies to this drug or its ingredients. Patients with impaired kidney function may have delayed excretion of the medication, so dosage adjustments should be made according to medical advice, and regular kidney function tests are important. During treatment with this medication, symptoms such as upper respiratory infection, nasopharyngitis, headaches, diarrhea, nausea, etc., may occur, and if these symptoms persist or become severe, medical personnel should be consulted. If taken in conjunction with other hypoglycemic agents like insulin or sulfonylureas, hypoglycemic symptoms may occur, so blood sugar should be monitored frequently, and immediate action should be taken if symptoms arise. Severe joint pain or skin disorders that produce blisters may occur, so if these symptoms occur, the doctor should be informed, and discontinuation of the medication may be necessary. Women who are pregnant or breastfeeding are advised not to take this drug as its safety has not been established, and it should not be used in children and adolescents under 18 years of age. In case of overdose, seek medical attention immediately, as it may be partially removed through hemodialysis, and appropriate measures should be taken according to medical advice. This medication may interact with certain drugs, so it is essential to inform the doctor or pharmacist of any other medications being taken, as specific medication adjustments may be needed. In elderly patients, kidney function may be impaired, thus requiring dosage adjustments and monitoring of kidney function.

Serious side effects

Hives, severe swelling (angioedema), anaphylaxis, severe skin reactions (Stevens-Johnson syndrome, exfoliative skin disease, rash, cutaneous vasculitis), acute pancreatitis (fatal/non-fatal hemorrhagic or necrotizing pancreatitis), sudden and severe headache, cardiac arrest, pneumonia among upper respiratory infections, diabetic complications, metabolic acidosis, acute renal failure, severe joint pain and disability, blistering dermatosis, rhabdomyolysis, severe hypoglycemia

Mild side effects

• Nasopharyngitis
• upper respiratory infection
• headaches
• diarrhea
• abdominal pain
• nausea
• constipation
• vomiting
• muscle pain
• limb pain

This medication should be stored in a tightly sealed container to prevent air exposure and should be kept at room temperature between 1 and 30 degrees Celsius. This will maintain the drug's efficacy and prevent degradation.

Appearance

A round, biconvex, film-coated tablet with a pale yellow-pink color

Package unit

28 tablets - 14 tablets/PTP[x 2], 30 tablets - 10 tablets/PTP[x 3]